Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Pharma Equity Group

0.10 DKK

-10.87 %

Less than 1K followers

PEG

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Compare
-10.87 %
+1.99 %
-30.27 %
-5.09 %
-46.05 %
-34.50 %
-73.72 %
-78.42 %
-99.61 %

Pharma Equity Group develops medicines for the treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The Company uses repositioning of existing medicines and takes drug candidates to a clinical Phase III stage, after which they are handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the Company.

Read more
Market cap
125.82M DKK
Turnover
326.23K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Coverage
Disclaimer
Claus Thestrup
Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 10.09.2025

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press releaseyesterday

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group
Regulatory press release12/1/2025, 12:10 PM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Regulatory press release11/26/2025, 3:40 PM

Corrective information regarding the Annual Report 2024 and the Interim Report for H1 2025 following an order from the Danish Business Authority

Pharma Equity Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release10/1/2025, 7:24 AM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point
Research9/10/2025, 6:31 AM by
Claus Thestrup, Philip Coombes

Pharma Equity Group (One-pager): Repositioning Strategy at an Inflection Point

PEG maintained its guidance with its H1 2025 results, for DKK 11m in partner-driven revenue. The recent approval to initiate its RNX- 011 Phase IIb clinical trial strengthens PEG’s partner negotiation position.

Pharma Equity Group
Regulatory press release9/2/2025, 8:03 AM

Correction: Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group
Regulatory press release9/1/2025, 11:06 AM

Pharma Equity Group's subsidiary, Reponex Pharmaceuticals A/S, receives regulatory approval to initiate pivotal clinical trial with RNX-011 for life-threatening peritonitis

Pharma Equity Group
Regulatory press release8/14/2025, 7:06 AM

Consolidated Interim Report 1 January – 30 June 2025

Pharma Equity Group
Regulatory press release7/1/2025, 3:31 PM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Regulatory press release5/28/2025, 8:29 AM

Pharma Equity Group A/S Launches New Strategy to Drive Growth and Shareholder Returns

Pharma Equity Group
Regulatory press release5/5/2025, 8:43 AM

Passing of the General Meeting of Pharma Equity Group A/S

Pharma Equity Group
Regulatory press release4/1/2025, 11:29 AM

The Board of Directors' resolution on the issuance of convertible loans

Pharma Equity Group
Pharma Equity Group (One-pager): Proof-of-Concept year 2025
Research3/31/2025, 2:16 PM by
Philip Coombes, Claus Thestrup

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

Pharma Equity Group (One-pager): Proof-of-Concept year 2025

Pharma Equity Group
Regulatory press release3/25/2025, 10:00 AM

Notice convening the annual general meeting in Pharma Equity Group A/S

Pharma Equity Group
Third party research3/24/2025, 9:13 AM

Pharma Equity Group: Advanced Discussions with Prospective Licensing Partners - Analyst Group

Pharma Equity Group (“PEG” or “the Company”) has recently refined the Company’s execution strategy, prioritizing resources toward three key candidates, RNX-051, RNX-011, and RNX-041, where the Company identifies the shortest path to market and strong...

Pharma Equity Group
Third party research3/21/2025, 5:53 AM

Pharma Equity Group: Analyst Group Comments on PEG’s Year-End Report for 2024

Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of March 2025.

Pharma Equity Group
Regulatory press release3/20/2025, 7:03 AM

Pharma Equity Group A/S - Annual Report 2024

Pharma Equity Group
Press release2/28/2025, 12:19 PM

2025 Financial Calendar

Pharma Equity Group
Regulatory press release2/28/2025, 11:56 AM

Change of executive management and organizational change in Pharma Equity Group A/S

Pharma Equity Group
Press release1/14/2025, 9:06 AM

Pharma Equity Group 2025 Financial Calendar

Pharma Equity Group
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.